Company Profile
TG Therapeutics Stock Price, News & Analysis
- Ticker:
- TGTX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
49.55 USD (-0.66%)
Close
Last updated: August 6, 2026
5.61B USD
Market cap
Why the stock is moving
As of Aug 6, 2026, TGTX closed down 0.66% at $49.55. No new same-company headline was identified in the current news window.
Company overview
B-Cell-Directed Therapies
TG Therapeutics develops and commercializes therapies targeting B cells in multiple sclerosis and other autoimmune diseases. Its portfolio combines an approved anti-CD20 antibody with alternative formulations and an allogeneic cell-therapy program.
BRIUMVI
BRIUMVI, or ublituximab, is a glycoengineered CD20 monoclonal antibody approved for relapsing forms of multiple sclerosis. The antibody is designed for efficient B-cell depletion at a relatively low dose and is commercialized in the United States and through partners internationally.
Formulation and Dosing Expansion
The company is conducting a pivotal program for subcutaneous ublituximab and the ENHANCE trial of a consolidated intravenous Day 1 and Day 15 dosing regimen. These studies aim to make administration more convenient while maintaining the established mechanism.
Azer-Cel in Progressive MS
Azer-cel is an allogeneic CAR-T therapy being evaluated in progressive multiple sclerosis and other autoimmune diseases. The program tests whether deeper immune-cell resetting can benefit patients beyond conventional antibody-mediated B-cell depletion.
Future catalysts
Topline ENHANCE pivotal data for consolidated intravenous BRIUMVI dosing expected in mid-2026.
Preliminary Phase 1 azer-cel data in progressive multiple sclerosis expected in the second half of 2026.
Pivotal subcutaneous BRIUMVI topline data expected around year-end 2026 or the first quarter of 2027.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of TG Therapeutics (TGTX)?
TG Therapeutics (TGTX) most recently closed at 49.55 USD, a -0.66% move versus the previous session.
What is the market cap of TG Therapeutics (TGTX)?
TG Therapeutics currently has a market capitalization of 5.61B USD on BioPharmSignal.
What does TG Therapeutics do?
B-Cell-Directed Therapies TG Therapeutics develops and commercializes therapies targeting B cells in multiple sclerosis and other autoimmune diseases. Its portfolio combines an approved anti-CD20 antibody with alternative formulations and an allogeneic cell-therapy program. BRIUMVI BRIUMVI, or ublituximab, is a glycoengineered CD20 monoclonal antibody...
On which exchange is TGTX stock listed?
TG Therapeutics (TGTX) is associated with NASDAQ, United States, Biopharma.
What is CAR-T?
Azer-Cel in Progressive MS Azer-cel is an allogeneic CAR-T therapy being evaluated in progressive multiple sclerosis and other autoimmune diseases.
Which conditions is TG Therapeutics targeting with CAR-T?
B-Cell-Directed Therapies TG Therapeutics develops and commercializes therapies targeting B cells in multiple sclerosis and other autoimmune diseases. Its portfolio combines an approved anti-CD20 antibody with alternative formulations and an allogeneic cell-therapy program. BRIUMVI BRIUMVI, or ublituximab, is a glycoengineered CD20 monoclonal antibody...
How does TG Therapeutics describe recent progress with CAR-T?
Topline ENHANCE pivotal data for consolidated intravenous BRIUMVI dosing expected in mid-2026. Preliminary Phase 1 azer-cel data in progressive multiple sclerosis expected in the second half of 2026. Pivotal subcutaneous BRIUMVI topline data expected around year-end 2026 or the first quarter of 2027.
What is ublituximab?
BRIUMVI BRIUMVI, or ublituximab, is a glycoengineered CD20 monoclonal antibody approved for relapsing forms of multiple sclerosis.